‘The Rock’ asks families to be Diabetes Aware in new PSA
NEW YORK The fact of the matter is the average person is inundated with more than 3,000 messages each day, and as a result has gotten pretty good at tuning most of those messages out. So breaking through that clutter with a Hollywood star that may make fans pause for even a second around an important healthcare message is an accomplishment in and of itself.
And if you look at the caliber of stars who have participated in breaking through that clutter with Novo Nordisk and the Entertainment Industry Foundation — Halle Berry, Dustin Hoffman and Kevin Kline — Dwayne "The Rock" Johnson is joining some pretty elite, attention-grabbing company.
And it doesn’t hurt that Novo Nordisk and the Entertainment Industry Foundation have chosen a popular family/action/adventure star to herald increased awareness around diabetes, either. Johnson’s most recent box office release — Walt Disney’s "Race to Witch Mountain" — already has grossed $106.4 million worldwide, which includes $67.2 million domestically. And the movie became available on DVD Aug. 4, which means Johnson will be top of mind among those movie buffs who recently made a trip to Blockbuster Video or checked their mailbox for their latest Netflix flick.
Medication adherence report reveals need for patient-specific interventions
NEW YORK Boehringer Ingelheim has done a major service to the industry with the release of this report. Closing the gap on patient compliance and adherence remains not only the best opportunity for retail pharmacy to grow the business at a time of waning big blockbuster drug introductions and continued pressure from generic competition, but also represents the best opportunity for this industry to “show what it’s got,” as the entire nation turn its attention to health reform.
Hundreds of billions of healthcare dollars are spent needlessly as a result of people not taking their medications as they are supposed to, to say nothing of the toll it’s taking on patient outcomes.
Reading between the lines here, one of the big reasons behind non-compliance could very well be the state of the economy. A public opinion poll of 1,025 adults conducted by the Kaiser Family Foundation in mid-July found that 49% of Americans are still taking cost-cutting measures when it comes to their healthcare: 33% are shifting to medicines available over-the-counter in favor of a doctor’s visit; 21% skipped a doctor-recommended medical test or treatment because of cost; and 15% cut prescription doses in half or skipped doses in an effort to stretch their medicines. And taking those kinds of cost-cutting measures — saving a co-pay today but risking an emergency room visit tomorrow — only helps to amplify the important role a pharmacist can play in helping their patients navigate cost-saving strategies in an effort to maintain/boost compliance.
“All of those things…are happening,” Ted Epperly, president of the American Academy of Family Physicians, told Drug Store News in the fall following a similar Kaiser survey, and its cutting deeper than just the working poor, he said. Patients who would fall into lower- and middle-income status are making similar cost-cutting decisions.
Also already happening is that pharmacist interceding on the patient’s behalf to help mitigate prescription-drug costs. “We’ve found that physicians were particularly receptive to calling on a patient’s behalf and giving suggestions on how that patient could save money, especially if it was a matter of a patient either not taking that medication at all or taking something [else] to address their condition,” Douglas Hoey, SVP and COO for the National Community Pharmacy Association, told Drug Store News this past fall.
Advanced Vision Research founder dies
WOBURN, Mass. Jeffrey Gilbard, 55, founder of Advanced Vision Research, died Aug. 12 at Massachusetts General Hospital in Boston from complications related to a bicycle accident.
Gilbard was best known for his pioneering research around dry eye disease, a condition caused by a chronic lack of moisture in the eye. He also is considered one of the first ophthalmologists and researchers to understand the correlation between nutrition and the health and wellness of the eye.
“Jeff Gilbard was an innovative, gifted ophthalmologist and researcher, who made several important contributions to our profession,” stated Edward Holland, director of Cornea Service at the Cincinnati Eye Institute. “He was the first person to understand the importance of tear film osmolarity and his development of hypotonic artificial tears containing bicarbonate and potassium is a landmark event in the treatment of dry eye disease. Dr. Gilbard was on the forefront of the treatment of ocular disease and nutritional supplements. Dr. Gilbard’s legacy will be the scientific papers he authored, the revolutionary products he developed to help patients with ocular surface and retinal disease and most notably the people whose lives he’ll continue to improve.”
“Our company is grieving the loss of its founder and our close friend, Dr. Jeffrey Gilbard,” stated Leigh Reynolds, Advanced Vision Research COO. “Over the past 12 years, I have worked closely with [Gilbard] to build AVR. Jeff’s vision for AVR to make products to prevent suffering due to dry eye and other eye diseases was very clear. We will continue his mission of improving people’s quality of life. This is what [Gilbard] would want us to do and there’s no better tribute to him than to continue his work.”
“[Gilbard] was blessed with extraordinary intellect and dedication,” commented Neil Donnenfeld, SVP global sales and marketing. “He combined the two and made a significant difference in the world. He had no greater satisfaction than to hear that one of AVR’s products helped a dry-eye sufferer — and he heard that frequently. His legacy will live on through the relief that dry-eye sufferers receive when they use one of his products. We have lost a giant of a man.”
Gilbard founded Advanced Vision Research in 1995 to market and distribute TheraTears, an over-the-counter eye drop for dry eye. TheraTears quickly became one of the best-selling eye lubricants on the market. His holistic approach to eye care included the use of nutritional supplements to improve the ocular surface and to treat and prevent retinal disease. This research resulted in additional products including TheraTears Nutrition, Macutrition and NutriDox.
The AVR executive team will led by COO Reynolds, who will continue to run the company. Donnenfeld and Ruth Webb, controller, will continue in their respective capacities.Born Feb. 19, 1954 and raised in Roslyn, N.Y., he was the son of a self-educated New York business entrepreneur Harris Gilbard and mother Frances Gilbard. He attended Brown University, receiving his Bachelor of Arts degree, Magna Cum Laude in 1975. He received his medical degree in 1979 from the College of Physicians and Surgeons at Columbia University. He was an Intern in Internal Medicine at Stanford University Medical Center and served his Ophthalmology residency at Harvard Medical School in the Massachusetts Eye and Ear Infirmary. He remained at Harvard as a Heed Fellow in Cornea. He was a clinical assistant professor of Ophthalmology at Harvard Medical School and director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center in Boston.
Dr. Jeffrey Gilbard is survived by his beloved wife of 19 years, Liz and his three children, who he adored and nurtured. He also leaves behind his twin brother Dr. Steven M. Gilbard, his older brother Dr. Robert J. Gilbard. A memorial service will take place on Monday at 11:00 am at Temple Shir Tikva, 141 Boston Post Road, Wayland, Mass.